Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents
Bibliographic Information Authors: Kishta S.S.; Kishta S.A.; El-Shenawy R. Journal: F1000Research Publisher: Faculty of 1000 Ltd Publication Date: 25 January 2017 Volume / Issue: Volume 5 Article No.: 223 ISSN: 20461402 DOI: 10.12688/f1000research.7970.3 Scopus: View on Scopus Document Type: Article Access: All Open Access; Gold Open Access; Green Open Access Authors and Affiliations Kishta S.S., Medical Biotechnology Lab, Microbial Biotechnology Department, National Research Center, Egypt, Cairo, Egypt; Kishta S.A., Department of Surgery, Theodor Bilharz Research Institute, Giza, Egypt; El-Shenawy R., Medical Biotechnology Lab, Microbial Biotechnology Department, National Research Center, Egypt, Cairo, Egypt Abstract Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs). However, despite successful viral clearance, many patients continue to have HCV-related d...